Obesity treatment is expected to shift gradually from a one-size-fits-all approach towards more personalised medicine, in which the obesity phenotype and presence of related conditions will determine the treatment strategy https://t.co/IFPyEU8bKn
#obesity
Retatrutide phase 3 obesity trial just came out and the results are genuinely insane:
- 28.3% bodyweight lost on 12mg over 80 weeks
- 70.3 pounds on avg. or 31.9 kg
- 45.3% of patients hit 30%+ weight loss (this is bariatric surgery territory)
- 30.3% weight loss (85 lbs) at 104 weeks in higher-BMI patients
- 65.3% of 12mg patients dropped below the obesity BMI threshold
- 19% loss on 4mg over 80 weeks (47.2 lbs) with fewer dropouts than placebo (4.1% vs 4.9%)
- significant drops in blood pressure, triglycerides, non-HDL cholesterol, waist circumference, and hsCRP
- no cardiac or liver signals
Retatrutide is going to completely overshadow tirzepatide and semaglutide, and take the throne as the best-selling drug of all time.
@Langosta1607 Pero Marvelous sunshine seguro tiene más estudios, a qué te dedicas, eres internista y doctora en epidemiología por Johns Hopkins? Porque seguro por eso te las sabes de todas todas
HIPERINSULINEMIA COMO CAUSA DE OBESIDAD Y ENFERMEDADES CARDIOMETABOLICAS
Revisión narrativa que aborda la cuestión.
¡¡¡A leer, zagales!!!
Link en mi bio
o
https://t.co/k7BPZlSAbB
🇪🇸 En los Carnavales de Cádiz se canta “Tango a Donald Trump”. Tienen que escucharlo, la letra es una maravilla.
España y su humor político impecable, valiente, contundente. Llevo dos días escuchándolos y no deja de emocionarme.
A new era in obesity treatment: medications like #semaglutide and #tirzepatide target hunger pathways, offering sustained weight loss of 15–21%. More potent therapies and next-gen biologics, dual and triple agonists, are under development.
https://t.co/vDcvZef9wB
Prediabetes remission without weight loss: a paradigm shift in diabetes prevention
@NatMetabolism
Un análisis post hoc del Prediabetes Lifestyle Intervention Study (PLIS) muestra que la remisión de la prediabetes sin pérdida de peso es posible y altamente protectora frente al desarrollo de DM2 ( ⬇️riesgo del 71%).
🔬 mecanismos
Mejoría de la sensibilidad a la insulina.
Aumento de la función de la célula β y de la sensibilidad β-GLP-1.
Redistribución del tejido adiposo (subcutáneo vs. visceral)
🔗 https://t.co/godnJY5lYB
👉Intensive Lipid-Lowering Therapy Following Acute Coronary Syndrome:
The Earlier the Better
💔After an acute coronary syndrome (ACS), time is cholesterol.
⌛️Delaying intensive LDL-C lowering means leaving patients exposed at their most vulnerable stage.
Evidence is compelling:
•EVOPACS, PACMAN-MI, HUYGENS → Early PCSK9i + statins achieve LDL goals in weeks & stabilize plaques.
•LAI-REACT → Triple oral therapy (statin + ezetimibe + bempedoic acid) cut LDL by ~60% within 1 week.
☝️Yet, in real-world practice, <50% of post-PCI patients reach LDL targets at follow-up, often due to inertia, underuse of combination therapy, or delayed lipid checks.
The lesson is clear:
➡️ Do not wait for the first outpatient visit.
➡️ Start combination lipid-lowering during hospitalization.
➡️ Aim for <55 mg/dL (or even <40 mg/dL in recurrent events).
💪“Strike early, strike hard.”
Early LDL-C reduction is not just about hitting numbers; it’s about plaque regression, stabilization, and preventing recurrent events when risk is highest.
🔓Open access https://t.co/9r8Ey12yxv
@society_eas